AI Article Synopsis
- Small interfering RNAs (siRNAs) are tiny RNA pieces that can make messenger RNA (mRNA) disappear, which helps control how much protein is made in our bodies.
- Givosiran is a special siRNA that helps treat a rare liver disease called acute hepatic porphyrias by targeting a specific part of the liver that creates toxic substances.
- The text talks about how givosiran works, its successful test results, and its importance for treating this disease and potentially helping with other medical problems in the future.
Article Abstract
Small interfering ribonucleic acids [siRNAs] are short ribonucleic acid (RNA) fragments cleaved from double-stranded RNA molecules that target and bind to specific sequences on messenger RNA (mRNA), leading to their destruction. Therefore, the siRNA down-regulates the formation of selected mRNAs and their protein products. Givosiran is one such siRNA that uses this mechanism to treat acute hepatic porphyrias. Acute hepatic porphyrias are a group of rare, inherited metabolic disorders, characterized by acute potentially life-threatening attacks as well as chronic symptoms with a negative impact on quality of life. It has four types, each associated with distinct enzyme defects in the heme biosynthesis pathway in the liver. By targeting the expression of hepatic 5-aminolevulinic acid [ALA] synthase-1 [ALAS1], givosiran can down-regulate levels of toxic metabolites, leading to biochemical and clinical improvement. Givosiran selectively targets hepatocytes due to its linkage to -acetylgalactosamine (GalNac) leading to its selective uptake via asialoglycoprotein receptors (ASGPR). We provide an up-to-date literature review regarding givosiran in the context of a clinical overview of the porphyrias, an overview of siRNAs for therapy of human disorders, the design and development of givosiran, key clinical trial results of givosiran for prevention of acute porphyric attacks, emerging concerns regarding chronic use of givosiran, and the overall management of acute hepatic porphyrias. These insights are important not only for the management of acute hepatic porphyrias but also for the emerging field of siRNAs and their role in novel therapies for various diseases.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9208469 | PMC |
| http://dx.doi.org/10.2147/DDDT.S281631 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Liver assistive devices in acute liver failure: Current use and future directions.
Best Pract Res Clin Gastroenterol
December 2024
Department of Critical Care Medicine, University of Alberta, Edmonton, Canada; Division of Gastroenterology (Liver Unit), University of Alberta, Edmonton, Canada. Electronic address:
Article Synopsis
- * The only certain treatment for ALF is liver transplantation (LT); however, some patients, especially those with acetaminophen-related liver failure, might recover with medical support instead of needing LT.
- * Extracorporeal liver support (ECLS) is a growing area of interest in treating ALF, aiming to help the liver by removing toxins and promoting regeneration, with two main types: artificial ECLS (like dialysis methods) and bioartificial ECLS (which uses live hepat
Evaluation and management of neurological complications in acute liver failure.
Best Pract Res Clin Gastroenterol
December 2024
Institute of Digestive & Liver Diseases, BLK Superspeciality Hospital, Delhi, India. Electronic address:
Neurological complications in acute liver failure are the most common cause of mortality in this group of patients. Almost all neurologic complications arise from underlying increase in intracranial pressure in ALF. In addition to symptomatic management, the treatment relies on measures to bring down ICP.
View Article and Find Full Text PDFAdvanced strategies for intensive care management of acute liver failure.
Best Pract Res Clin Gastroenterol
December 2024
Department of Anesthesiology and Critical Care, Hospital of the University of Pennsylvania, Philadelphia, PA, 19104, USA.
Acute liver failure (ALF) is defined as the loss of hepatic function in conjunction with hepatic encephalopathy and coagulopathy. There is histological evidence of profound hepatocyte damage. If it is not aggressively managed, ALF can be fatal within a few days.
View Article and Find Full Text PDFDefinitions, etiopathogenesis and epidemiology of ALF.
Best Pract Res Clin Gastroenterol
December 2024
Department of Gastroenterology and Human Nutrition Unit, All India Institute of Medical Sciences, New Delhi, India. Electronic address:
Acute liver failure (ALF) is a rare but preventable cause of acute hepatic dysfunction which is associated with significant mortality, unless treated appropriately. There are significant regional variations in the etiologies of ALF globally and this determines the outcomes of the disease as well as the long-term survival in patients receiving liver transplantation for management. Improvements in understanding of disease pathophysiology and critical care medicine have led to better outcomes over the last few decades.
View Article and Find Full Text PDFCoagulopathy in acute liver failure.
Best Pract Res Clin Gastroenterol
December 2024
Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. Electronic address:
Acute liver failure (ALF) is a rare but rapidly progressing syndrome, marked by severe liver dysfunction and altered mental status. While definitions of ALF vary across different guidelines, with timelines ranging from 4 to 26 weeks between jaundice onset and encephalopathy, the key defining features remain encephalopathy and coagulopathy. Elevated coagulation markers, particularly prothrombin time and international normalized ratio, have traditionally been associated with bleeding risks.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!